Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Januvia Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

NCT01289990
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Placebo, Sitagliptin 100mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

NCT02025907
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

NCT07567781
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-722, Midazolam, Metformin, Digoxin, Pitavastatin, Sitagliptin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

NCT01619332
View directory record Official record
Conditions
Type II Diabetes
Interventions
Placebo, Sitagliptin, LEZ763
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
6
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 23, 2026, 4:25 PM EDT
Completed No phase listed Observational

Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data

NCT04882813
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Dapagliflozin, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
87,727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 1 Interventional

Drug Interaction Study Between Dorzagliatin and Sitagliptin

NCT03790839
View directory record Official record
Conditions
Patients
Interventions
Sitagliptin, Dorzagliatin
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
30 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients

NCT00751114
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, Sitagliptin, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 70 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 23, 2026, 4:25 PM EDT
Terminated Phase 4 Interventional Results available

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

NCT03738878
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan, LCZ696, Bradykinin, Substance P, BNP, Sitagliptin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Not applicable Interventional Results available

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

NCT00775684
View directory record Official record
Conditions
Pre-diabetes, Type 2 Diabetes
Interventions
Exenatide, Sitagliptin, Glimepiride
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 2 Interventional Results available

Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02683525
View directory record Official record
Conditions
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Interventions
Sitagliptin
Drug
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin DPPIV Inhibitor add-on Study

NCT00984867
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
45
States / cities
Huntsville, Alabama • Ozark, Alabama • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Not applicable Interventional Results available

The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus

NCT01092663
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Colesevelam HCl, Sitagliptin
Drug
Lead sponsor
KineMed
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
San Francisco, California • Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 23, 2026, 4:25 PM EDT
Completed No phase listed Observational Results available

A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

NCT01077323
View directory record Official record
Conditions
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
Interventions
exenatide, Other antidiabetic therapies, No diabetes therapy
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
363,766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 1 Interventional

Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis

NCT01721382
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sitagliptin
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 20 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 2Phase 3 Interventional

Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study

NCT04409795
View directory record Official record
Conditions
Type 1 Diabetes, Monogenic Diabetes
Interventions
Metformin Extended Release Oral Tablet, Sitagliptin
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
Up to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

NCT01455870
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650 60 mcg/day, sitagliptin
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Long Beach, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 2 Interventional

A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy

NCT01169090
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
SK-0403, Placebo, Sitagliptin
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2011 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy

NCT01488279
View directory record Official record
Conditions
Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
Interventions
Dexamethasone 2.5 mg and Sitagliptin 100 mg, Dexamethasone 2.5 mg and placebo tablet
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin

NCT01054118
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
JNJ-38431055, Sitagliptin 100 mg, JNJ-38431055 + Sitagliptin 100 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 3, 2013 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial

NCT00851903
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, Sitagliptin, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 71 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

NCT00838903
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, sitagliptin, glimepiride, metformin, placebo albiglutide, placebo sitagliptin, placebo glimepiride
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,049 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
317
States / cities
Birmingham, Alabama • Dothan, Alabama • Hueytown, Alabama + 254 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 23, 2026, 4:25 PM EDT
Completed Phase 4 Interventional Results available

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

NCT01378117
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
Interventions
Sitagliptin, glargine, lispro
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 23, 2026, 4:25 PM EDT
Not listed Phase 4 Interventional

Bone Turnover in Type 2 Diabetes Patients

NCT00732121
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 27, 2010 · Synced Sep 23, 2026, 4:25 PM EDT
Terminated Phase 4 Interventional Results available

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

NCT00936663
View directory record Official record
Conditions
Type 2 Diabetes, End Stage Renal Disease
Interventions
Placebo, Sitagliptin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 23, 2026, 4:25 PM EDT